We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A Step Towards a Nasal Spray Treatment for Parkinson’s Disease
News

A Step Towards a Nasal Spray Treatment for Parkinson’s Disease

A Step Towards a Nasal Spray Treatment for Parkinson’s Disease
News

A Step Towards a Nasal Spray Treatment for Parkinson’s Disease

Credit: Diana Polekhina/Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A Step Towards a Nasal Spray Treatment for Parkinson’s Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.

Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.

Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed.

Increased dosage


Professor David Smith, from the University of York’s Department of Chemistry, said: “The current drug used for Parkinson’s Disease is effective to a point, but after a long period of use the body starts to breakdown the drug before it gets to the brain where it is most needed.

“This means increased dosage is necessary, and in later stages, sometimes, instead of tablets, the drug has to be injected.  Investigations into nasal sprays have long been of interest as a more effective delivery because of its direct route to the brain via the nerves that service the nose, but the challenge here is to find a way of making it adhere to the nasal tissue long enough to release a good dosage of the drug.”

The researchers created a gel, loaded with levodopa, that could flow into the nose as a liquid and then rapidly change to a thin layer of gel inside the nose.  The method was tested in animal models by a team at King’s College London, where levodopa was successfully released from the gel into the blood and directly to the brain. 

Better uptake


Professor Smith said: “The results indicated that the gel gave the drug better adhesion inside the nose, which allowed for better levels of uptake into both the blood and brain.”

The team are now working to incorporate these materials in nasal spray devices to progress to clinical trials in humans.  The approach may also be relevant to other neurodegenerative diseases such as Alzheimer’s.

Khuloud Al-Jamal, Professor of Drug Delivery and Nanomedicine from King’s College London, said: “Not only did the gel perform better than a simple solution, but the brain uptake was better than that achieved using intravenous injection of the drug. This suggests that nasal delivery of Parkinson’s drugs using this type of gel may have clinical relevance.” 

Reference: Wang JT-W, Rodrigo AC, Patterson AK, et al. Enhanced delivery of neuroactive drugs via nasal delivery with a self-healing supramolecular gel. Advanced Science. 2021. doi: 10.1002/advs.202101058

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement